LumiraDx Collaborates with AstraZeneca and Everton to Establish a Heart and Lung Screening Hub for its NT-proBNP Test Across England
Shots:
- With AstraZeneca & Everton, LumiraDx intends to initiate a community-based heart & lung screening Hub across Merseyside, England for the early detection of heart failure, COPD, asthma & other chronic conditions. Liverpool University Hospitals NHS Foundation Trust, Lenus Health, Us2.ai, ArtiQ & Pumping Marvellous are also associated with this initiative
- LumiraDx’s NT-proBNP test leverages AI & eliminates the requirement of phlebotomy. The NT-proBNP test uses a fingerstick sample of blood to detect chronic conditions
- The initiative will also offer lifestyle reviews & advice to those in need. LumiraDx expects to launch the heart & lung screening Hub in November 2023
Ref: Globenewswire | Image: AstraZeneca
Related News:- AstraZeneca’ Soliris (eculizumab) Receives the NMPA’s Approval for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
